IMPROVEMENTS IN AIR RING DESIGN INCREASE COOLING EFFICIENCY, FILM OUTPUT.MICK R.1977; PLAST. DESIGN PROCESSG; U.S.A.; DA. 1977; VOL. 17; NO 8; PP. 30-32Article

FIRST-TRIMESTER SERUM PROLACTIN LEVELS IN NORMAL AND COMPLICATED PREGNANCIESRISS P; MICK R; SPONA J et al.1980; GYNECOL. OBSTETR. INVEST.; CHE; DA. 1980; VOL. 11; NO 2; PP. 113-118; BIBL. 10 REF.Article

DER VERLAUF DER SERUM PROLAKTINSPIEGEL BEI DER LAKTATIONSHEMMUNG MIT 2-BROM-ALPHA -ERGOCRYPTIN (CB 154). = L'EVOLUTION DU TAUX DE PROLACTINE SERIQUE DANS L'INHIBITION DE LA LACTATION PAR LA 2-BROM-ALPHA -ERGOCRYPTINE (CB 154)GERSTNER G; MICK R; SPONA J et al.1977; WIEN. KLIN. WSCHR.; OESTERR.; DA. 1977; VOL. 89; NO 19; PP. 6,4-667; ABS. ANGL.; BIBL. 12 REF.Article

EIN VERGLEICH DER WIRKSAMKEIT VON NYSTATIN UND AMPHOTERICIN B BEI DER THERAPIE WEIBLICHER GENITALMYKOSEN = UNE COMPARAISON DE L'EFFICACITE DE LA NYSTATINE ET DE L'AMPHOTERICINE B DANS LE TRAITEMENT DES MYCOSES GENITALES DE LA FEMMEMICK R; MULLER TYL EM; NEUFELD T et al.1975; WIEN. MED. WSCHR.; OESTERR.; DA. 1975; VOL. 125; NO 9; PP. 131-135; BIBL. 16 REF.Article

DER EINFLUSS EINER AKTIVEN EINSTELLUNG ZUR GEBURTSEINLEITUNG AUF DAS VORKOMMEN VON PATHOLOGISCHEM FRUCHTWASSER - EIN VERGLEICH DER GEBURTSJAHRGAENGE 1967 UND 1976 = L'EFFET D'UNE ATTITUDE ACTIVE A L'EGARD DE L'INDUCTION DU TRAVAIL SUR L'APPARITION D'UN LIQUIDE AMNIOTIQUE PATHOLOGIQUE - UNE COMPARAISON DES ANNEES 1967 ET 1976GRUENBERGER W; MICK R; WAGENBICHLER P et al.1978; Z. GEBURTSH. PERINATOL.; DEU; DA. 1978; VOL. 182; NO 6; PP. 434-439; ABS. ENG; BIBL. 33 REF.Article

POSTPARTALE LAKTATIONSHEMMUNG MIT 2-BROM-A-ERGOCRYPTIN = INHIBITION POSTPARTUM DE LA LACTATION PAR LA BROMOCRIPTINEGERSTNER G; MICK R; REINOLD E et al.1978; WIEN. MED. WSCHR.; AUT; DA. 1978; VOL. 128; NO 22; PP. 704-706; BIBL. 15 REF.Article

Statistical approaches to pharmacodynamic modeling : motivations, methods, and misperceptionsMICK, R; RATAIN, M. J.Cancer chemotherapy and pharmacology. 1993, Vol 33, Num 1, pp 1-9, issn 0344-5704Article

Model-guided determination of maximum tolerated dose in phase I clinical trials : evidence for increased precisionMICK, R; RATAIN, M. J.Journal of the National Cancer Institute. 1993, Vol 85, Num 3, pp 217-223, issn 0027-8874Article

Coastal rock cliff erosion by collapse at Puys, France: The role of impervious marl seams within chalk of NW EuropeDUPERRET, Anne; GENTER, Albert; MORTIMORE, Rory N et al.Journal of coastal research. 2002, Vol 18, Num 1, pp 52-61, issn 0749-0208Article

Hematuria in sickle cell anemia : not always benign : evidence for excess frequency of sickle cell anemia in African Americans with renal cell carcinomaBARON, B. W; MICK, R; BARON, J. M et al.Acta haematologica. 1994, Vol 92, Num 3, pp 119-122, issn 0001-5792Article

High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow : a role for peripheral blood progenitor transplantMYERS, S. E; MICK, R; WILLIAMS, S. F et al.Bone marrow transplantation (Basingstoke). 1994, Vol 13, Num 4, pp 449-454, issn 0268-3369Article

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics : Prediction of biliary index and intestinal toxicityMICK, R; GUPTA, E; VOKES, E. E et al.Journal of clinical oncology. 1996, Vol 14, Num 7, pp 2012-2019, issn 0732-183XArticle

Interferon treatment for hairy cell leukemia : an update on a cohort of 69 patients treated from 1983-1986GOLOMB, H. M; RATAIN, M. J; MICK, R et al.Leukemia. 1992, Vol 6, Num 11, pp 1177-1180, issn 0887-6924Article

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agentsRATAIN, M. J; MICK, R; SCHILSKY, R. L et al.Journal of the National Cancer Institute. 1993, Vol 85, Num 20, pp 1637-1643, issn 0027-8874Article

Physician-determined patient risk of toxic effects : impact on enrollment and decision making in phase I cancer trialsMICK, R; LANE, N; DAUGHERTY, C et al.Journal of the National Cancer Institute. 1994, Vol 86, Num 22, pp 1685-1693, issn 0027-8874Article

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphomaZIMMERMAN, T. M; MICHEISON, G. C; MICK, R et al.Journal of clinical apheresis (Print). 1999, Vol 14, Num 1, pp 31-34, issn 0733-2459Article

Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft functionSHAW, L. M; MICK, R; NOWAK, I et al.Journal of clinical pharmacology. 1998, Vol 38, Num 3, pp 268-275, issn 0091-2700Article

In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopeniaRATAJCZAK, M. Z; RATAJCZAK, J; MACHALINSKI, B et al.Blood. 1998, Vol 91, Num 1, pp 353-359, issn 0006-4971Conference Paper

The treatment of hairy cell leukaemia : an updateGOLOMB, H. M; RATAIN, M. J; MICK, R et al.Leukemia. 1992, Vol 6, pp 24-27, issn 0887-6924, SUP2Conference Paper

Pharmacologically based dosing of etoposide : a means of safely increasing dose intensityRATAIN, M. J; MICK, R; SCHILSKY, R. L et al.Journal of clinical oncology. 1991, Vol 9, Num 8, pp 1480-1486, issn 0732-183XArticle

Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies?MICK, R; BEGG, C. B; ANTMAN, K. H et al.Breast cancer research and treatment. 1989, Vol 13, Num 1, pp 33-38, issn 0167-6806, 6 p.Article

Treatment of early chronic lymphotic leukemia: intermittent chlorambucil versus observationSHUSTIK, C; MICK, R; SILVER, R et al.Hematological oncology. 1988, Vol 6, Num 1, pp 7-12, issn 0278-0232Article

Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignanciesLARSON, R. A; MICK, R; SPIELBERGER, R. T et al.Journal of clinical oncology. 1996, Vol 14, Num 1, pp 188-195, issn 0732-183XArticle

Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapyZIMMERMAN, T. M; MICK, R; BENDER, J. G et al.Bone marrow transplantation (Basingstoke). 1995, Vol 15, Num 6, pp 923-927, issn 0268-3369Article

Increased incidence of second neoplasms in patients treated with interferon α 2b for hairy cell leukemia : a clinicopathologic assessmentKAMPMEIER, P; SPIELBERGER, R; DICKSTEIN, J et al.Blood. 1994, Vol 83, Num 10, pp 2931-2938, issn 0006-4971Article